The survival benefit of carfilzomib, dexamethasone and daratumumab (KdD) in relapsed or refractory multiple myeloma is relatively consistent regardless of prior lines of therapy. In the phase III CANDOR trial published last year, KdD was shown to significantly improve PFS (HR 0·63) compared to carfilzomib plus dexamethasone (Kd). Now, a subgroup analysis of the CANDOR ...
KdD an important treatment option for patients with RRMM
By Mardi Chapman
3 Jun 2021